Upadacitinib for Immune Checkpoint Inhibitor–Related Dermatitis
This nonrandomized clinical trial examines the safety and efficacy of oral upadacitinib in the treatment of patients with severe immune checkpoint inhibitor–related dermatitis.
Authors
- Chengshui Chen
- Xinyu Liang (ORCID: https://orcid.org/0000-0003-0964-4294)
- Yan Zou (ORCID: https://orcid.org/0000-0003-0504-3088)
- Huijuan He
- Zheng Peng
- Yi He
- Shixiu Wu
Institutions
- Wenzhou Medical University (CN)
- Zhejiang Lab (CN)
Publication Details
- Journal
- JAMA Oncology
- Published
- 2026-03-05
- DOI
- https://doi.org/10.1001/jamaoncol.2026.0136
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China